Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00241085 |
This is a study of whether valsartan affects levels of proteinuria in patients with type 2 diabetes and hypertension.
Condition | Intervention | Phase |
---|---|---|
Proteinuria Hypertension Type 2 Diabetes |
Drug: valsartan |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Multi-Center, Double Blind, Randomized, Parallel Group Study to Evaluate the Effects of Valsartan on Proteinuria in Hypertensive Subjects With Type 2 Diabetes Mellitus |
Estimated Enrollment: | 369 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Mild to moderate hypertension, Mild renal dysfunction, Type 2 diabetes,
Exclusion Criteria:
Pregnant or breast feeding, Type 1 diabetes
Other protocol criteria apply
Study ID Numbers: | CVAL489A2417 |
Study First Received: | October 14, 2005 |
Last Updated: | June 1, 2006 |
ClinicalTrials.gov Identifier: | NCT00241085 History of Changes |
Health Authority: | United States: Food and Drug Administration |
proteinuria hypertension valsartan type 2 diabetes |
Metabolic Diseases Urination Disorders Diabetes Mellitus Vascular Diseases Endocrine System Diseases Cardiovascular Agents Antihypertensive Agents Signs and Symptoms |
Proteinuria Urologic Diseases Diabetes Mellitus, Type 2 Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder Valsartan Hypertension |
Metabolic Diseases Urination Disorders Diabetes Mellitus Vascular Diseases Endocrine System Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Urological Manifestations |
Signs and Symptoms Proteinuria Urologic Diseases Therapeutic Uses Diabetes Mellitus, Type 2 Cardiovascular Diseases Glucose Metabolism Disorders Valsartan Hypertension |